Tarceva and Pancreatic Cancer
When used in combination with gemcitabine, Tarceva® (erlotinib) is approved for the treatment of pancreatic cancer (cancer that begins in the tissue of the pancreas, a gland that lies behind the stomach). Specifically, Tarceva is approved for the treatment of pancreatic cancer that has advanced, spread to other areas of the body (metastasized), or cannot be removed with surgery.
(To learn more about treating pancreatic cancer with this drug, click Tarceva Uses. This article also takes an in-depth look at the other conditions Tarceva is approved to treat and includes details on how it works, who can use it, and more.)